Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/164918
Title: Disease-specific changes in Reelin protein and mRNA in neurodegenerative diseases
Author: Lidón Gil, Laia
Urrea Zazurca, Laura
Llorens Torres, Franc
Gil Fernández, Vanessa
Álvarez, Ignacio
Diez-Fairen, Monica
Aguilar, Miguel
Pastor, Pau
Zer, Inga
Alcolea, Daniel
Lleó Bisa, Alberto
Vidal, Enric
Gavín Marín, Rosalina
Ferrer, Isidro (Ferrer Abizanda)
Río Fernández, José Antonio del
Keywords: Malalties neurodegeneratives
Glicoproteïnes
Neurodegenerative Diseases
Glycoproteins
Issue Date: 19-May-2020
Publisher: MDPI
Abstract: Reelin is an extracellular glycoprotein that modulates neuronal function and synaptic plasticity in the adult brain. Decreased levels of Reelin activity have been postulated as a key factor during neurodegeneration in Alzheimer's disease (AD) and in aging. Thus, changes in levels of full-length Reelin and Reelin fragments have been revealed in cerebrospinal fluid (CSF) and in post-mortem brains samples of AD patients with respect to non-AD patients. However, conflicting studies have reported decreased or unchanged levels of full-length Reelin in AD patients compared to control (nND) cases in post-mortem brains and CSF samples. In addition, a compelling analysis of Reelin levels in neurodegenerative diseases other than AD is missing. In this study, we analyzed brain levels of RELN mRNA and Reelin protein in post-mortem frontal cortex samples from different sporadic AD stages, Parkinson's disease with dementia (PDD), and Creutzfeldt-Jakob disease (sCJD), obtained from five different Biobanks. In addition, we measured Reelin protein levels in CSF samples of patients with mild cognitive impairment (MCI), dementia, or sCJD diagnosis and a group of neurologically healthy cases. The results indicate an increase in RELN mRNA in the frontal cortex of advanced stages of AD and in sCJD(I) compared to controls. This was not observed in PDD and early AD stages. However, Reelin protein levels in frontal cortex samples were unchanged between nND and advanced AD stages and PDD. Nevertheless, they decreased in the CSF of patients with dementia in comparison to those not suffering with dementia and patients with MCI. With respect to sCJD, there was a tendency to increase in brain samples in comparison to nND and to decrease in the CSF with respect to nND. In conclusion, Reelin levels in CSF cannot be considered as a diagnostic biomarker for AD or PDD. However, we feel that the CSF Reelin changes observed between MCI, patients with dementia, and sCJD might be helpful in generating a biomarker signature in prodromal studies of unidentified dementia and sCJD.
Note: Reproducció del document publicat a: https://doi.org/10.3390/cells9051252
It is part of: Cells, 2020, vol. 9, num. 5, p. 1252-1271
URI: http://hdl.handle.net/2445/164918
Related resource: https://doi.org/10.3390/cells9051252
ISSN: 2073-4409
Appears in Collections:Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)

Files in This Item:
File Description SizeFormat 
701681.pdf2.61 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons